The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
Help: Registration number
ACTRN12626000582358p
Ethics application status
Help: Ethics application status
Submitted, not yet approved
Date submitted
Help: Date submitted
23/04/2026
Date registered
Help: Date registered
11/05/2026
Date last updated
Help: Date last updated
11/05/2026
Date data sharing statement initially provided
Help: Data sharing statement date
11/05/2026
Type of registration
Help: Type of registration
Prospectively registered

Titles & IDs
Public title
Does a 6-month very brief physical activity intervention during chemotherapy increase the physical activity levels of people with cancer compared to usual care?
Scientific title
A very brief intervention for Physical Activity behaviour change (Measure It!) during Chemotherapy Cancer Care: a pilot randomised controlled trial
Additional trial identifiers [1] 317098 0
None
Universal Trial Number (UTN)
Trial acronym
Related trial records

Health condition
Health condition(s) studied:
cancer 341634 0
physical inactivity 341635 0
Condition category
Condition code
Cancer 337723 337723 0 0
Any cancer
Public Health 337724 337724 0 0
Health promotion/education
Physical Medicine / Rehabilitation 337725 337725 0 0
Other physical medicine / rehabilitation

Intervention/exposure
Study type
Interventional
Description of the intervention or exposure
Measure It! intervention:
Measure It! includes a self-report and objective measure of physical activity plus brief tailored physical activity advice provided by their cancer care clinician. Participants will be asked about their current level of physical activity using the Physical Activity Vital Sign (On average how many days per week do you engage in moderate or greater physical activity?; On average how many minutes per day do you engage in activity at this level?), taking less than 30 seconds to complete. Participants will also be asked to provide the average number of steps per day they completed in the last week according to their wearable activity tracker or smartphone app or Fitbit. The physical activity guidelines will be very briefly discussed (2 minutes) at each measurement. An example of the very brief physical activity advice provided is ‘moderate intensity physical activity means you should be able to talk in full sentences but not sing’, or ‘any activity is better than none’, or ‘if you feel no worse after 5-10 minutes of walking, it’s ok to keep walking’.

Participants will be encouraged to safely increase their physical activity levels during the 6-month intervention period aiming to progress towards the public health physical activity guidelines, that is, accumulate 150 to 300 minutes of moderate intensity aerobic physical activity or 75 to 150 minutes of vigorous intensity aerobic physical activity or a combination of both each week. Intervention participants will receive 5 Measure It! interventions from cancer care clinicians over 6-months. Measure It! sessions received will be recorded on a checklist. The Measure It! intervention will be delivered face-to-face during chemotherapy treatment but may be delivered via telehealth. From our pilot (ACTRN12616000566437) and type I hybrid (ACTRN12622001187730) trials in general and cardiac rehabilitation populations, the total time required for measuring physical activity and provision of brief advice was < 5 mins, classifying this as a very brief intervention.
Intervention code [1] 333856 0
Behaviour
Intervention code [2] 333857 0
Prevention
Intervention code [3] 333858 0
Lifestyle
Description of the comparator or control
The comparator group will receive usual care during the 6-month study period. Usual care will consist of chemotherapy treatment for 4-6 months and follow-up with an oncologist.
Control group
Active

Outcomes
Primary outcome [1] 345190 0
Physical activity levels: A triaxial commercial accelerometer (ActiGraph GT3X, Fort Walton Beach, FL) will be used to objectively assess physical activity. Patients will be asked to wear the accelerometer on their right hip, while awake, for 7-consecutive days at baseline, 3 and 6-months as an outcome measure only. The accelerometer will be returned to the Chemotherapy Day Unit or via mail in a reply-paid post pack provided. All data will be downloaded, screened and categorised according to commonly used algorithms in this population to determine time spent in different physical activity intensities.
Timepoint [1] 345190 0
Baseline, 3 and 6-months post-enrolment
Secondary outcome [1] 460815 0
Daily steps: Physical activity levels: A triaxial commercial accelerometer (ActiGraph GT3X, Fort Walton Beach, FL) will be used to objectively assess physical activity. Patients will be asked to wear the accelerometer on their right hip, while awake, for 7-consecutive days at baseline, 3 and 6 months as an outcome measure only. The accelerometer will be returned to the Chemotherapy Day Unit or via mail in a reply-paid post pack provided. All data will be downloaded and screened.
Timepoint [1] 460815 0
Baseline, 3 and 6 months post-enrolment
Secondary outcome [2] 460816 0
Health-related Quality of Life: The European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 (EORTC QLQ-C30) is a self-administered quality of life questionnaire. The EORTC QLQC-30 is a validated and reliable 30-item self-report tool measuring functional health, symptom burden and health-related quality-of-life. It includes five functional scales (physical functioning, cognitive functioning, emotional functioning, social functioning and role functioning); and nine scales to assess common physical and psychosocial effects of cancer.
Timepoint [2] 460816 0
Baseline, 3 and 6 months post-enrolment
Secondary outcome [3] 460817 0
Fatigue: the European Organisation for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30 Fatigue scale (EORTC QLQC-FA12 scale) is a sub-scale of the self-administered quality of life survey. The Fatigue scale is calculated from 3-items in the EORTC QLQ-C30.
Timepoint [3] 460817 0
Baseline, 3 and 6 months post-enrolment
Secondary outcome [4] 460818 0
Anxiety: The Hospital Anxiety and Depression Scale (HADS) questionnaire is a 14-item self-reporting questionnaire comprised of 4-point Likert-scaled items covering the occurrence of symptoms of anxiety (HADS-A) and depression (HADS-D) over the past 2 weeks. Each item on the questionnaire is scored from 0–3, so that a person can score between 0 (best outcome) and 21 (worst outcome) for either anxiety or depression.
Timepoint [4] 460818 0
Baseline, 3 and 6 months post-enrolment
Secondary outcome [5] 460819 0
Depression: The Hospital Anxiety and Depression Scale (HADS) questionnaire is a 14-item self-reporting questionnaire comprised of 4-point Likert-scaled items covering the occurrence of symptoms of anxiety (HADS-A) and depression (HADS-D) over the past 2 weeks. Each item on the questionnaire is scored from 0–3, so that a person can score between 0 (best outcome) and 21 (worst outcome) for either anxiety or depression.
Timepoint [5] 460819 0
Baseline, 3 and 6 months post-enrolment

Eligibility
Key inclusion criteria
Eligible participants must:
- be greater than or equal to 18 years old,
- have any cancer diagnosis suitable for chemotherapy,
- a life expectancy greater than or equal to 6 months,
- receiving chemotherapy treatment for greater than or equal to 4-6 months,
- have a wearable activity tracker OR smartphone (step tracker app) OR computer/tablet,
- have no serious medical conditions that could limit participation in moderate physical activity,
- have no severe functional impairments due to medical and psychiatric conditions,
- have adequate English and cognitive skills to participate in the study.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Healthy volunteers
No
Key exclusion criteria
Participants will be excluded if they have unstable medical conditions or are unable to wear an accelerometer due to disability, for example, if they are confined to a wheelchair.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
After participant baseline measures have been completed, the investigator will be contacted via telephone or email by the assessing cancer care clinician to reveal random allocation to one of two groups (1:1 ratio): Measure It! or usual care over 6 months.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
An investigator in a remote location and not involved in recruitment or assessments will use a computer to generate a random number sequence which is consecutively numbered. Randomisation will occur at an individual patient level.
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?


The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Not Applicable
Type of endpoint/s
Efficacy
Statistical methods / analysis
Analyses will be carried out following intention-to-treat principles. Linear (for continuous outcome data) and generalised linear (for binary and count outcome data) fixed-effects models will be used for between group comparisons at 6 months and interactions analyses adjusting for baseline measures as well as demographic characteristics, such as gender, and other potential covariates, such as chemotherapy unit. All analyses will be conducted using either SPSS or STATA. Significance level will be set at p<0.05.


Recruitment
Recruitment status
Not yet recruiting
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT
Recruitment hospital [1] 29434 0
Icon Cancer Centre Canberra - Bruce
Recruitment hospital [2] 29435 0
National Capital Private Hospital - Garran
Recruitment postcode(s) [1] 45753 0
2617 - Bruce
Recruitment postcode(s) [2] 45754 0
2605 - Garran

Funding & Sponsors
Funding source category [1] 321685 0
Charities/Societies/Foundations
Name [1] 321685 0
Cancer Council ACT
Country [1] 321685 0
Australia
Primary sponsor type
Individual
Name
Prof Nicole Freene, University of Canberra
Address
Country
Australia
Secondary sponsor category [1] 324512 0
Individual
Name [1] 324512 0
Rebecca Cesnik, University of Canberra
Address [1] 324512 0
Country [1] 324512 0
Australia

Ethics approval
Ethics application status
Submitted, not yet approved
Ethics committee name [1] 320218 0
University of Canberra Human Research Ethics Committee
Ethics committee address [1] 320218 0
Ethics committee country [1] 320218 0
Australia
Date submitted for ethics approval [1] 320218 0
15/03/2026
Approval date [1] 320218 0
Ethics approval number [1] 320218 0

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 149798 0
Prof Nicole Freene
Address 149798 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 149798 0
Australia
Phone 149798 0
+61 2 6201 5550
Fax 149798 0
Email 149798 0
Contact person for public queries
Name 149799 0
Nicole Freene
Address 149799 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 149799 0
Australia
Phone 149799 0
+61 2 6201 5550
Fax 149799 0
Email 149799 0
Contact person for scientific queries
Name 149800 0
Nicole Freene
Address 149800 0
University of Canberra, University Drive, Bruce, ACT, 2617
Country 149800 0
Australia
Phone 149800 0
+61 2 6201 5550
Fax 149800 0
Email 149800 0

Data sharing statement
Will the study consider sharing individual participant data?
Yes
Will there be any conditions when requesting access to individual participant data?
Persons/groups eligible to request access:
• Researchers interested in a cancer care and physcial activity.

Conditions for requesting access:
• De-identified data for this trial will be available upon request by emailing the principal investigator: [email protected]

What individual participant data might be shared?
• Physical activity levels, Health-related quality of life, fatigue, depression, anxiety and socio-demographic variables (eg: age, gender).

What types of analyses could be done with individual participant data?
• Statistical

When can requests for individual participant data be made (start and end dates)?
From:
2028

To:
2032. This data will be available for 5 years.

Where can requests to access individual participant data be made, or data be obtained directly?
• De-identified data for this trial will be available upon request by emailing the principal investigator: [email protected]

Are there extra considerations when requesting access to individual participant data?
No


What supporting documents are/will be available?

No Supporting Document Provided


Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
No additional documents have been identified.